We’re excited to share our latest research: “ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic Cancer.”

https://www.biorxiv.org/content/10.1101/2024.11.11.622928v1

Targeting metabolic dependencies like ELOVL6 in c-MYC-driven cancers could open new avenues in PDAC treatment, offering hope for better patient outcomes. Follow us for updates as we continue exploring the therapeutic potential of lipid metabolism in cancer

#PDAC